RefleXion Submits FDA 510(k) for Anchor Point Tracking, Advancing the Next Generation of SCINTIX Autonomous Radiotherapy

HAYWARD, Calif.--(BUSINESS WIRE)-- #SCINTIX--RefleXion Medical, an external beam theranostic oncology company, today announced it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for Anchor PointTM Tracking, a next-generation tumor tracking technology designed for use with the new RefleXion® X2 platform. “Anchor Point Tracking represents the next major advancement in autonomous radiotherapy,” said Todd Powell, CEO and president of Refle